NVS - Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript)
2024-06-03 17:24:06 ET
Novartis AG (NVS)
Investor Event at ASCO Conference Call
June 02, 2024 07:00 PM ET
Company Participants
Parag Mahanti - Investor Relations
Shreeram Aradhye - President of Global Drug Development and Chief Medical Officer
Jeff Legos - Global Head of Oncology & Hematology Drug Development
Reshema Kemps-Polanco - Chief Commercial Officer of U.S. Business
Rodney Gillespie - International Therapeutic Area Head, Oncology Novartis
Conference Call Participants
Emmanuel Papadakis - Deutsche Bank
Steve Scala - TD Cowen
Emily Field - Barclays
Mark Purcell - Morgan Stanley
Seamus Fernandez - Guggenheim Security
Peter Welford - Jefferies
Presentation
Parag Mahanti
Hi, everyone. Thank you so much for joining us at the Novartis Investor Event at ASCO 2024. Welcome to everyone in the room and all those who are joining us in the webcast. Some of you are in Europe, so thank you for staying up late. We are very excited to discuss the Phase 3 ASC4FIRST study data for Scemblix in newly diagnosed CMO patients. But first, a couple of housekeeping notes.
We will start with the presentation. The slides are uploaded on the website, followed by Q&A and then a reception. For the Q&A, we'll take questions from both the room and online. For those in the room, please wait for the mic, and state your name before asking the question. Those online, please submit your questions via the webcast. We request you to limit to one question at a time so that we get to everyone's questions. Our aim is to wrap up the presentation and Q&A by about 7:00 PM.
With us today, we have Shreeram Aradhye, President of Global Drug Development at Novartis and our Chief Medical Officer; Jeff Legos, Global Head of Oncology and Hematology Drug Development; and Reshema Kemps-Polanco, Chief Commercial Officer of our U.S. Business. Finally, what you have all been waiting for the safe harbor statement.
The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the Company's forms 20-F and its most recently quarterly results on form 6-K that respectively were filed with and furnished to the U.S. Securities and Exchange Commission.
With that, I'd like to hand it over to Shreeram to get us started.
Shreeram Aradhye
Thank you, Parag. Good evening to everybody. Hello to those joining us on the web in Europe. Special moment for us at ASCO here and I hope that you've all had a good week, good few days, I guess, at ASCO. We are delighted all to be here because we are celebrating a pretty special moment for Novartis....
Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript)